Compared to 10 or 15 years ago, the drug mixture has completely changed. The products on the market today are of course much more efficient, but also much higher in price, and correspondingly, it’s become much more challenging for payers to cover them – especially with limited resources. It is crucial now more than ever to define specific criteria and appropriate benchmarks to ensure that drugs admitted into reimbursement perform as ...